<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04703101</url>
  </required_header>
  <id_info>
    <org_study_id>20-001156</org_study_id>
    <secondary_id>NCI-2020-06479</secondary_id>
    <secondary_id>20-001156</secondary_id>
    <nct_id>NCT04703101</nct_id>
  </id_info>
  <brief_title>Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer</brief_title>
  <official_title>Organ Preservation for Patients With Locally Advanced Rectal Adenocarcinoma: Evaluating the Efficacy of Short Course Radiation Therapy Followed by FOLFOX or CapeOX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial investigates how well short-course radiation therapy followed by&#xD;
      combination chemotherapy works in treating patients with stage II-III rectal cancer.&#xD;
      Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy&#xD;
      drugs, such as leucovorin, fluorouracil, oxaliplatin, and capecitabine, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells, by stopping them from&#xD;
      dividing, or by stopping them from spreading. Giving short-course radiation therapy and&#xD;
      combination chemotherapy may reduce the need for surgery and therefore improve quality of&#xD;
      life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Complete clinical response (cCR) rate of patients with clinical T3 and/or node-positive M0&#xD;
      rectal cancer being treated with short-course radiation therapy (SCRT) followed by 16 weeks&#xD;
      of modified leucovorin, fluorouracil, and oxaliplatin (mFOLFOX)/capecitabine and oxaliplatin&#xD;
      (CapeOX).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. 1-year local recurrence free survival and 1-year progression free survival of the entire&#xD;
      cohort, the cohort that initially undergoes non-operative management (NOM), and the cohort&#xD;
      that initially undergoes total mesorectal excision (TME).&#xD;
&#xD;
      II. Physician-reported acute and late &gt;= grade 3 toxicity rates. III. 1-year post-treatment&#xD;
      patient health-related quality of life and anorectal function as per Patient Reported&#xD;
      Outcomes Measurement and Information System (PROMIS).&#xD;
&#xD;
      IV. Explore how Signatera's residual disease test correlates with patient's cCR rates, local&#xD;
      recurrence, progression-free, and overall survival rates.&#xD;
&#xD;
      V. Explore radiomics features from longitudinal diffusion weighted magnetic resonance imaging&#xD;
      (MRI) (diffusion weighted imaging [DWI]) data and build a predictive model for treatment&#xD;
      effect (complete response) in rectal cancer patients undergoing SCRT.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo SCRT in the form of intensity-modulated radiation therapy (IMRT) over 5&#xD;
      fractions daily for 5 consecutive days. Beginning 11-18 days after the last day of radiation&#xD;
      therapy, patients receive either oxaliplatin intravenously (IV) and leucovorin IV on day 1&#xD;
      and fluorouracil IV on days 1-3 (mFOLFOX6) or oxaliplatin IV on day 1 and capecitabine orally&#xD;
      (PO) twice daily (BID) on days 1-14 (CapeOX). Treatment with mFOLFOX6 repeats every 2 weeks&#xD;
      for up to 8 cycles, and treatment with CapeOX repeats every 3 weeks for up to 6 cycles in the&#xD;
      absence of disease progression or unacceptable toxicity. At 8-12 weeks after completion of&#xD;
      all therapy, patients with residual tumor undergo TME. Patients with cCR undergo NOM.&#xD;
&#xD;
      After completion of study treatment, patients who underwent NOM are followed up every 3&#xD;
      months for 2 years, then every 6 months for 3 years. TME patients are followed up every 3-6&#xD;
      months for 2 years, then every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Analysts blinded to patient outcome and sample order</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Complete clinical response rate</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Kaplan-Meier analysis will be carried out and used to estimate for the entire cohort as well the non-operational management (NOM) and total mesorectal excision (TME) cohorts separately.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local recurrence-free survival</measure>
    <time_frame>At 1 year</time_frame>
    <description>Kaplan-Meier analysis will be carried out and used to estimate for the entire cohort as well the NOM and TME cohorts separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>At 1 year</time_frame>
    <description>Kaplan-Meier analysis will be carried out and used to estimate for the entire cohort as well the NOM and TME cohorts separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Physician-reported acute and late &gt;= grade 3 toxicity rates for the entire cohort will be graded according to Common Terminology Criteria for Adverse Events version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>At 1 year</time_frame>
    <description>Will be assessed by Patient Reported Outcomes Measurement and Information System and calculated and presented as a composite score. These scores will be calculated for the entire cohort as well as the NOM and TME cohorts separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anorectal function</measure>
    <time_frame>At 1 year</time_frame>
    <description>Will be assessed by Patient Reported Outcomes Measurement and Information System and calculated and presented as a composite score. These scores will be calculated for the entire cohort as well as the NOM and TME cohorts separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signatera's residual disease test</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Cox proportional hazards regression analysis will be used to assess the association of circulating tumor deoxyribonucleic acid with clinical response rates, local recurrent, progression-free, and overall survival rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction of complete clinical response rate status by radiomics</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The relationship between complete clinical response as a binary variable and longitudinal radiomics features from a sequence of four diffusion weighted imaging data points will be assessed via a logistic regression model with a random effect term to account for within-subject correlation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Locally Advanced Rectal Carcinoma</condition>
  <condition>Rectal Adenocarcinoma</condition>
  <condition>Stage II Rectal Cancer AJCC v8</condition>
  <condition>Stage IIA Rectal Cancer AJCC v8</condition>
  <condition>Stage IIB Rectal Cancer AJCC v8</condition>
  <condition>Stage IIC Rectal Cancer AJCC v8</condition>
  <condition>Stage III Rectal Cancer AJCC v8</condition>
  <condition>Stage IIIA Rectal Cancer AJCC v8</condition>
  <condition>Stage IIIB Rectal Cancer AJCC v8</condition>
  <condition>Stage IIIC Rectal Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (IMRT, mFOLFOX6, CapeOX, TME)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo SCRT in the form of IMRT over 5 fractions daily for 5 consecutive days. Beginning 11-18 days after the last day of radiation therapy, patients receive either oxaliplatin IV and leucovorin IV on day 1 and fluorouracil IV on days 1-3 (mFOLFOX6) or oxaliplatin IV on day 1 and capecitabine PO BID on days 1-14 (CapeOX). Treatment with mFOLFOX6 repeats every 2 weeks for up to 8 cycles, and treatment with CapeOX repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. At 8-12 weeks after completion of all therapy, patients with residual tumor undergo TME. Patients with cCR undergo NOM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (IMRT, mFOLFOX6, CapeOX, TME)</arm_group_label>
    <other_name>Ro 09-1978/000</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (IMRT, mFOLFOX6, CapeOX, TME)</arm_group_label>
    <other_name>5 Fluorouracil</other_name>
    <other_name>5 Fluorouracilum</other_name>
    <other_name>5 FU</other_name>
    <other_name>5-Fluoro-2,4(1H, 3H)-pyrimidinedione</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-Fu</other_name>
    <other_name>5FU</other_name>
    <other_name>AccuSite</other_name>
    <other_name>Carac</other_name>
    <other_name>Fluoro Uracil</other_name>
    <other_name>Fluouracil</other_name>
    <other_name>Flurablastin</other_name>
    <other_name>Fluracedyl</other_name>
    <other_name>Fluracil</other_name>
    <other_name>Fluril</other_name>
    <other_name>Fluroblastin</other_name>
    <other_name>Ribofluor</other_name>
    <other_name>Ro 2-9757</other_name>
    <other_name>Ro-2-9757</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Treatment (IMRT, mFOLFOX6, CapeOX, TME)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
    <other_name>Radiation, Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (IMRT, mFOLFOX6, CapeOX, TME)</arm_group_label>
    <other_name>Folinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (IMRT, mFOLFOX6, CapeOX, TME)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Ai Heng</other_name>
    <other_name>Aiheng</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Diaminocyclohexane Oxalatoplatinum</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>Eloxatine</other_name>
    <other_name>JM-83</other_name>
    <other_name>Oxalatoplatin</other_name>
    <other_name>Oxalatoplatinum</other_name>
    <other_name>RP 54780</other_name>
    <other_name>RP-54780</other_name>
    <other_name>SR-96669</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (IMRT, mFOLFOX6, CapeOX, TME)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Surveillance</intervention_name>
    <description>Undergo NOM</description>
    <arm_group_label>Treatment (IMRT, mFOLFOX6, CapeOX, TME)</arm_group_label>
    <other_name>Epidemiology / Surveillance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Mesorectal Excision</intervention_name>
    <description>Undergo TME</description>
    <arm_group_label>Treatment (IMRT, mFOLFOX6, CapeOX, TME)</arm_group_label>
    <other_name>TME</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed rectal adenocarcinoma&#xD;
&#xD;
          -  Patients must have stage II (cT3, cN0) or stage III (cT1-3, cN1-3) tumor as staged by&#xD;
             MRI&#xD;
&#xD;
          -  No evidence of metastatic disease&#xD;
&#xD;
          -  Resectable primary lesion&#xD;
&#xD;
          -  Karnofsky performance status (KPS) &gt;= 70 or Eastern Cooperative Oncology Group (ECOG)&#xD;
             0-2&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 1.5 cell/mm^3&#xD;
&#xD;
          -  Hemoglobin (Hgb) &gt; 8.0 gm/dL&#xD;
&#xD;
          -  Platelets (PLT) &gt; 150,000/mm^3&#xD;
&#xD;
          -  Total bilirubin &lt; or equal to 1.5 x upper limit of normal&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; or equal to&#xD;
             three times upper limit of normal&#xD;
&#xD;
          -  If a woman is of childbearing potential, a negative serum pregnancy test must be&#xD;
             documented prior to initiation of radiation therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active treatment of a separate malignancy&#xD;
&#xD;
          -  Distant metastatic disease as assessed by staging positron emission tomography&#xD;
             (PET)/computed tomography (CT) or CT of the chest and abdomen within 6 weeks of&#xD;
             starting radiation therapy&#xD;
&#xD;
          -  Prior radiotherapy to the region of the study cancer that would result in overlap of&#xD;
             radiation therapy fields&#xD;
&#xD;
          -  Pregnant and/or breastfeeding&#xD;
&#xD;
          -  Medical/psychological contraindication to MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Raldow</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent Basehart</last_name>
    <phone>310 267-8954</phone>
    <email>vbasehart@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Raldow</last_name>
      <phone>310-825-9771</phone>
      <email>araldow@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Ann Raldow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

